BMY
stock Healthcare Drug Manufacturers - GeneralOverall Mixed · 51%
- Fundamentals Fair
- Trajectory Steady
- Leadership Normal
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Mixed 4 of 5 trend signals bullishRSI 56 — firm momentum, not yet overbought.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 26
- Open
- $55.40
- +0.02%
- Close
- $57.52
- +3.85%
- Current
- $57.52
- Prev close
- $55.39
- Today
- 24.00M
- 3-mo avg
- 11.43M
Earningscalendar synced from Yahoo 23d ago
- Most recent
- Apr 3082 days ago
- Next expected
- Jul 30in 9 days
Recent earnings dates
- Apr 30 82 days ago
- Feb 5 166 days ago
- Oct 30, 2025 264 days ago
- Jul 31, 2025 355 days ago
Past earnings dates come from BMY’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 23d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), BMY’s fundamentals read as fair overall.
At 16.1x, the price is a reasonable multiple of the company's annual profit.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
A 4.3% yield is a healthy, generally sustainable level of cash income.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 14.6% margin is solid, in the ordinary range for a profitable company.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 38.2% return on equity is strong; the company compounds owners' capital well.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 7.8% return on assets is reasonable for a company of this kind.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 3.87, the company leans heavily on borrowing, which adds risk if results weaken.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.26, short-term assets cover short-term bills with a little room to spare.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue fell 0.2% from the prior year; the top line is contracting.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
The company returned to profit after a loss-making prior year.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 23d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Net income | $7.0B | $6.3B | $8.0B | -$8.9B | $7.1B |
| Diluted EPS | $3.12 | $2.95 | $3.86 | $-4.41 | $3.46 |
| Dividend / share | $2.01 | $2.19 | $2.31 | $2.42 | $2.49 |
| Total assets | $109.3B | $96.8B | $95.2B | $92.6B | $90.0B |
| Total liabilities | $73.3B | $65.7B | $65.7B | $76.2B | $71.5B |
| Shareholder equity | $35.9B | $31.1B | $29.4B | $16.3B | $18.5B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.2B | $11.9B | $12.3B | $11.2B | $12.3B | $12.2B | $12.5B | $11.5B |
| Net income | $1.7B | $1.2B | $72.0M | $2.5B | $1.3B | $2.2B | $1.1B | $2.7B |
| Diluted EPS | $0.83 | $0.60 | $0.05 | $1.20 | $0.64 | $1.08 | $0.54 | $1.31 |
| Dividend / share | $0.60 | $0.60 | $0.62 | $0.62 | $0.62 | $0.62 | $0.63 | $0.63 |
Leadershipsynced from SEC 23d ago
- Boerner Christopher S. Chief Executive Officer · Director
- Elkins David V EVP, Chief Financial Officer
- Gallman Cari EVP, General Counsel
- Hickey Benjamin President, RayzeBio Org.
- Hoch Lynelle President, Cell Therapy Org.
- Holzer Phil M SVP and Controller
- Lenkowsky Adam EVP, Chief Commercial Officer
- Massacesi Cristian EVP,Chief Med Offr,Head of Dev
- Meyers Gregory Scott EVP, Chief Digital & Tech Off.
- Plenge Robert M EVP, Chief Research Officer
- Poole Ahn Amanda EVP, Chief People Officer
- Shanahan Karin EVP, Chief Supply Chain & Ops
- Shibutani Hiroshi Chris EVP, Chief Strategy Officer
- Short Bartie Wendy EVP, Corporate Affairs
- Arduini Peter J Director
- Haller Julia A Director
- Mcmullen Michael R. Director
- Price Paula A Director
- Rice Derica W Director
- Samuels Theodore R. Ii Director
- Vousden Karen H Director
- Yale Phyllis R Director
Officers and board are drawn from BMY’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- Apr 30 +5.2% one-day move
- Dec 31, 2025 FY2025 net income +179% YoY
- Dec 3, 2025 +5.6% one-day move
- Oct 30, 2025 +7.1% one-day move
- Oct 28, 2025 New 6-month low (-16% off peak)
- Oct 1, 2025 +5.2% one-day move
- Jul 31, 2025 New 6-month low (-31% off peak)
- Jul 31, 2025 −5.8% one-day move
- Jul 25, 2025 Officer or director change reported in an 8-K
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Dividendssynced from Yahoo 23d ago
- 2025 total
- $2.48
- 2026 so far
- $1.262 payments
- 2026 projected
- $2.52+1.6% vs 2025
Projection scales BMY’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.
Payment history
- Apr 2 $0.63
- Jan 2 $0.63
- Oct 3, 2025 $0.62
- Jul 3, 2025 $0.62
- Apr 4, 2025 $0.62
- Jan 3, 2025 $0.62
- Oct 4, 2024 $0.60
- Jul 5, 2024 $0.60
- Apr 4, 2024 $0.60
- Jan 4, 2024 $0.60
- Oct 5, 2023 $0.57
- Jul 6, 2023 $0.57
- Apr 6, 2023 $0.57
- Jan 5, 2023 $0.57
- Oct 6, 2022 $0.54
- Jun 30, 2022 $0.54
- Mar 31, 2022 $0.54
- Jan 6, 2022 $0.54
- Sep 30, 2021 $0.49
- Jul 1, 2021 $0.49
Recent SEC filingssynced from SEC 23d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report